<DOC>
	<DOCNO>NCT02117024</DOCNO>
	<brief_summary>This study test whether vaccination viagenpumatucel-L combine low-dose cyclophosphamide prolong survival patient non-small cell lung cancer ( NSCLC ) fail 2 3 prior line therapy incurable metastatic disease compare chemotherapy alone . Patients randomize 2 1 viagenpumatucel-L arm chemotherapy alone arm , respectively .</brief_summary>
	<brief_title>A Phase 2 Study Viagenpumatucel-L ( HS-110 ) Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Nonsmall cell lung adenocarcinoma At least 2 3 prior line therapy incurable metastatic NSCLC Suitable conventional single agent chemotherapy Disease progression study entry Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) â‰¤ 1 ; PS=2 patient may consider Central nervous system ( CNS ) metastases may permit must treat neurologically stable Adequate laboratory parameter Willing able comply protocol sign inform consent Female patient childbearing potential fertile male patient must agree use effective form contraception throughout study participation Received systemic anticancer therapy radiation therapy within previous 14 day Received 3 line prior conventional therapy advance disease Human immunodeficiency virus ( HIV ) , hepatitis B C , severe/uncontrolled infection intercurrent illness , unrelated tumor , require active therapy Any condition require concurrent systemic immunosuppressive therapy Known immunodeficiency disorder Known leptomeningeal disease Other active malignancy Prior treatment cancer vaccine indication Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>lung</keyword>
	<keyword>cancer</keyword>
	<keyword>gp96</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Heat Biologics</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>erlotinib</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>docetaxel</keyword>
	<keyword>pemetrexed</keyword>
</DOC>